BACKGROUND: The purpose of this study was to investigate the early diagnosis and outcomes of surgical treatment of primary duodenal adenocarcinoma (PDAC) for curative purpose. METHOD: Thirty-two PDAC patients treated surgically between February 1990 and September 2006 were analyzed retrospectively. RESULTS: All 32 patients underwent laparotomy, including 18 patients (56.3%) pancreaticoduodenectomy (PD), six patients (18.7%) segmental resection (SR), and eight patients bypass procedures. R0 resections were obtained in 22 patients; the other 10 procedures were palliative. The total 1-, 3-, and 5-year survival rates in this study were 86.2% (25/29), 48.3% (14/29), and 20.7% (6/29), respectively, moreover, the 1-, 3-, and 5-year survival rates in patients with R0 resection were 100.0% (19/19), 73.7% (14/19), and 31.6%(6/19), which were significantly higher than those (50.0% = 5/10, 0%, and 0%) in patients with palliative operation (P > 0.05), respectively. Furthermore, the 5-year survival rate was 27.8% (5/18) in pancreaticoduodenectomy patients and 16.7% (1/6) in segmental resection patients, and there was no significant difference between the above two procedures (P > 0.05). CONCLUSION: PD is suggested for tumor located at the first and second portion of the duodenum, and SR may be appropriate for the selected patients, especially for tumors of the distal duodenum.
BACKGROUND: The purpose of this study was to investigate the early diagnosis and outcomes of surgical treatment of primary duodenal adenocarcinoma (PDAC) for curative purpose. METHOD: Thirty-two PDAC patients treated surgically between February 1990 and September 2006 were analyzed retrospectively. RESULTS: All 32 patients underwent laparotomy, including 18 patients (56.3%) pancreaticoduodenectomy (PD), six patients (18.7%) segmental resection (SR), and eight patients bypass procedures. R0 resections were obtained in 22 patients; the other 10 procedures were palliative. The total 1-, 3-, and 5-year survival rates in this study were 86.2% (25/29), 48.3% (14/29), and 20.7% (6/29), respectively, moreover, the 1-, 3-, and 5-year survival rates in patients with R0 resection were 100.0% (19/19), 73.7% (14/19), and 31.6%(6/19), which were significantly higher than those (50.0% = 5/10, 0%, and 0%) in patients with palliative operation (P > 0.05), respectively. Furthermore, the 5-year survival rate was 27.8% (5/18) in pancreaticoduodenectomy patients and 16.7% (1/6) in segmental resection patients, and there was no significant difference between the above two procedures (P > 0.05). CONCLUSION:PD is suggested for tumor located at the first and second portion of the duodenum, and SR may be appropriate for the selected patients, especially for tumors of the distal duodenum.
Authors: Juan Manuel Ramia; Jesús Villar; Antonio Palomeque; Karim Muffak; Alfonso Mansilla; Daniel Garrote; José Antonio Ferrón Journal: Cir Esp Date: 2005-04 Impact factor: 1.653
Authors: F G Bakaeen; M M Murr; M G Sarr; G B Thompson; M B Farnell; D M Nagorney; D R Farley; J A van Heerden; L M Wiersema; C D Schleck; J H Donohue Journal: Arch Surg Date: 2000-06
Authors: George A Poultsides; Lyen C Huang; John L Cameron; Richard Tuli; Leslie Lan; Ralph H Hruban; Timothy M Pawlik; Joseph M Herman; Barish H Edil; Nita Ahuja; Michael A Choti; Christopher L Wolfgang; Richard D Schulick Journal: Ann Surg Oncol Date: 2011-12-14 Impact factor: 5.344
Authors: Peter T Kalogerinis; John E Poulos; Andrew Morfesis; Anthony Daniels; Stavroula Georgakila; Thomas Daignualt; Alexandros G Georgakilas Journal: BMC Gastroenterol Date: 2010-09-17 Impact factor: 3.067